Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis.

IF 1 Q4 PHARMACOLOGY & PHARMACY FARMACIA HOSPITALARIA Pub Date : 2024-11-29 DOI:10.1016/j.farma.2024.10.017

Joaquín Borrás-Blasco, Silvia Cornejo, Alejandro Valcuende-Rosique, Rebeca Alcala, Ana Navalon Bono

{"title":"Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis.","authors":"Joaquín Borrás-Blasco, Silvia Cornejo, Alejandro Valcuende-Rosique, Rebeca Alcala, Ana Navalon Bono","doi":"10.1016/j.farma.2024.10.017","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study was to evaluate the real-world persistence, effectiveness, and safety of secukinumab in adult patients with moderate-to-severe psoriasis in two different hospitals.Methods: Retrospective cohort study that used registries and medical records from 2 different hospitals (February 2015-March 2024). Adults with moderate-to-severe psoriasis who initiated secukinumab treatment were identified and followed-up until March 2024, or disenrollment. Baseline demographic and clinical characteristics studied included sex, age at diagnosis, weight, prior failed treatments, duration of treatment and psoriasis area severity index (PASI) score. Adherence was measured using medication possession ratio (MPR); patients with MPR ≥ 80% were considered adherent. Persistence, effectiveness, safety, and dosage regimen of secukinumab were collected. Kaplan-Meier analysis was used to estimate secukinumab persistence using 1-year intervals.Results: A total of 88 patients with moderate-to-severe psoriasis were included, of whom 45 (51.1%) had not received prior biological treatment. Baseline PASI score was 15.0 ± 2.9 and patients received 1.4 ± 0.8 prior biological treatments. The most common previous biological treatments included anti-TNFα (60.5%) and ustekinumab (20.9%). 34 (38.6%) patients discontinued secukinumab treatment due to the following reasons. 19 (21.5%) due to a lack of effectiveness, 8 (9.2%), due to achieve only a partial response, and 7 (7.9%) due to adverse effects. Secukinumab persistence was 61.5 ± [21.7] months for all patients. When performing a subgroup analysis, non-naïve patients obtained a persistence of 63.5 ± [12.4] months followed by 54.1 ± [14.8] months for naïve patients (p = .804). Secukinumab persistence at 1 year, 2 years, and 3 years was 72.7%, 51.1%, and 39.8%, respectively.Conclusions: Secukinumab demonstrated persistence in more than 70% of patients with moderate to severe psoriasis after the first year of treatment.","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA HOSPITALARIA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.farma.2024.10.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of this study was to evaluate the real-world persistence, effectiveness, and safety of secukinumab in adult patients with moderate-to-severe psoriasis in two different hospitals.

Methods: Retrospective cohort study that used registries and medical records from 2 different hospitals (February 2015-March 2024). Adults with moderate-to-severe psoriasis who initiated secukinumab treatment were identified and followed-up until March 2024, or disenrollment. Baseline demographic and clinical characteristics studied included sex, age at diagnosis, weight, prior failed treatments, duration of treatment and psoriasis area severity index (PASI) score. Adherence was measured using medication possession ratio (MPR); patients with MPR ≥ 80% were considered adherent. Persistence, effectiveness, safety, and dosage regimen of secukinumab were collected. Kaplan-Meier analysis was used to estimate secukinumab persistence using 1-year intervals.

Results: A total of 88 patients with moderate-to-severe psoriasis were included, of whom 45 (51.1%) had not received prior biological treatment. Baseline PASI score was 15.0 ± 2.9 and patients received 1.4 ± 0.8 prior biological treatments. The most common previous biological treatments included anti-TNFα (60.5%) and ustekinumab (20.9%). 34 (38.6%) patients discontinued secukinumab treatment due to the following reasons. 19 (21.5%) due to a lack of effectiveness, 8 (9.2%), due to achieve only a partial response, and 7 (7.9%) due to adverse effects. Secukinumab persistence was 61.5 ± [21.7] months for all patients. When performing a subgroup analysis, non-naïve patients obtained a persistence of 63.5 ± [12.4] months followed by 54.1 ± [14.8] months for naïve patients (p = .804). Secukinumab persistence at 1 year, 2 years, and 3 years was 72.7%, 51.1%, and 39.8%, respectively.

Conclusions: Secukinumab demonstrated persistence in more than 70% of patients with moderate to severe psoriasis after the first year of treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

长期持续使用secukinumab治疗中重度牛皮癣患者。

目的：本研究的目的是评估两家不同医院的成人中重度牛皮癣患者使用secukinumab的现实世界持续性、有效性和安全性。方法：回顾性队列研究，使用2家不同医院（2015年2月- 2024年3月）的登记和医疗记录。开始接受secukinumab治疗的中度至重度牛皮癣成人患者被确定并随访至2024年3月，或取消入组。研究的基线人口统计学和临床特征包括性别、诊断年龄、体重、既往治疗失败、治疗持续时间和牛皮癣区域严重程度指数（PASI）评分。采用药物占有比（MPR）衡量依从性；MPR ≥ 80%的患者为粘附性。收集了secukinumab的持久性、有效性、安全性和给药方案。Kaplan-Meier分析以1年为间隔估计secukinumab的持久性。结果：共纳入88例中重度牛皮癣患者，其中45例（51.1%）未接受过生物治疗。基线PASI评分为15.0 ± 2.9，患者既往接受生物治疗1.4 ± 0.8。以前最常见的生物治疗包括抗tnf α(60.5%)和ustekinumab（20.9%）。34例（38.6%）患者由于以下原因停止了secukinumab治疗。19例（21.5%）因缺乏有效性，8例（9.2%）因仅达到部分缓解，7例（7.9%）因不良反应。所有患者的Secukinumab持续时间为61.5 ± [21.7]个月。在进行亚组分析时，non-naïve患者的持续时间为63.5 ± [12.4]个月，naïve患者的持续时间为54.1 ± [14.8]个月（p = .804）。Secukinumab在1 年、2 年和3 年的持续时间分别为72.7%、51.1%和39.8%。结论：在治疗一年后，超过70%的中度至重度牛皮癣患者的Secukinumab持续存在。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

FARMACIA HOSPITALARIA PHARMACOLOGY & PHARMACY-

CiteScore

1.90

自引率

21.40%

发文量

审稿时长

37 days

期刊介绍： Una gran revista para acceder a los mejores artículos originales y revisiones de la farmacoterapia actual. Además, es Órgano de expresión científica de la Sociedad Española de Farmacia Hospitalaria, y está indexada en Index Medicus/Medline, EMBASE/Excerpta Médica, Alert, Internacional Pharmaceutical Abstracts y SCOPUS.